A Phase 3 interventional study of Live, attenuated dengue serotype 1, 2, 3, and 4 virus and Yellow fever vaccine in Dengue, Dengue Hemorrhagic Fever and Yellow Fever, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 2 sites in 2 countries. Open to participants aged 12 Months to 13 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Severe Dengue by Sanofi — none open to participants now, none under way, none of them phase 3. Severe Dengue · Sanofi.
Among the 29 studies in Severe Dengue by Sanofi, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2011, is one of 9 in phase 3, and was the 16th registered.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
Browse Severe Dengue studies →None of the 29 studies in Severe Dengue by Sanofi is open now. The open studies under Severe Dengue, anywhere →
Of the 4 Severe Dengue studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 12 Months to 13 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2011.
This study's enrollment of 792 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Median enrollment 345 across the 26 interventional studies, 3,203 across the 3 observational. Of the 29 that completed or were terminated, 24 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Severe Dengue by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study was designed to evaluate whether the first CYD dengue vaccination can be administered concomitantly with Stamaril® yellow fever vaccine during the same day and visit, but at 2 different sites of administration.
Primary Objective:
Secondary Objectives:
All participants received a total of 9 injections during the study. Vaccine immunogenicity assessments for dengue neutralizing antibodies was performed in a randomized subset of participants. All participants were followed-up for safety during the study and for 6 months after the last CYD dengue vaccination.
65 studies on the registry are indexed under Severe Dengue; 5 are open to participants now.
This study's enrollment of 792 is above the median of 170 across 52 interventional studies indexed under Severe Dengue.
Browse Severe Dengue studies →Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
First submitted after Sanofi Pasteur became part of Sanofi.
Compared within Severe Dengue, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dengue. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month \[M\] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus · Biological: Yellow fever vaccine · Biological: Measles, mumps, and rubella (MMR) vaccine · Biological: Pneumococcal Conjugated Vaccine · Biological: Hepatitis A Pediatric Vaccine · Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine
Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
Biological: Live, attenuated dengue serotype 1, 2, 3, and 4 virus · Biological: Yellow Fever Vaccine · Biological: Placebo (NaCl) · Biological: Measles, mumps, and rubella vaccine · Biological: Pneumococcal Conjugated Vaccine · Biological: Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine · Biological: Hepatitis A Pediatric Vaccine
0.5 mL, subcutaneous at age 12, 18, and 24 months
Also known as: CYD Dengue Vaccine
0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
Also known as: Stamaril®
Drug page: Measles-Mumps-Rubella Vaccine
0.5 mL, subcutaneous at age 12 to 13 months.
Also known as: MMR vaccine
0.5 mL, intramuscular at age 13 to 14 months
0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
0.5 mL, intramuscular at age 19 to 20 months
Also known as: DTaP IPV//Hib Vaccine
0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
Also known as: CYD dengue vaccine
0.5 mL, subcutaneous at age 12 to 13 months
Also known as: Stamaril®
0.5 mL, subcutaneous at age 12 to 13 months
Also known as: NaCl 0.9%
Drug page: Measles-Mumps-Rubella Vaccine
0.5 mL, subcutaneous at age 13 to 14 months
Also known as: MMR vaccine
0.5 mL, intramuscular at age 13 to 14 months
0.5 mL, intramuscular at age 19 to 20 months
Also known as: DTaP IPV//Hib Vaccine
0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dilution \[dil\]) in flavivirus non-immune participants (defined as those with YF antibodies \<10 \[1/dil\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).
Time frame: 28 days Post-Injection 1
Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>= 10 (1/dil) in participants YF-seronegative at baseline or 4-fold increase from pre- to post-YF antibody titers in participants YF-seropositive at baseline.
Time frame: 28 days Post-Injection 1
Geometric Mean Titers (GMTs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTs against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.
Time frame: Pre-Injection 1 and 28-days Post-Injection 1
Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTs ratios against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.
Time frame: Pre-Injection 1 and 28- days Post-Injection 1
Percentage of All Participants With YF Antibody Titers of >=10 (1/Dil) Before and After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dil) regardless of the flavivirus status of participants at baseline.
Time frame: Pre-Injection 1 and 28-days Post-Injection 1
GMTs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue plaque reduction neutralization test (PRNT) assay.
Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3
GMTRs of Dengue Virus Antibodies Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTRs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.
Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3
Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. Seroconversion was defined as antibody titers \>= 10 (1/dil) against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains.
Time frame: Pre-Injection 1 and 28-days Post-Injections 2 and 3
Percentage of Participants With Antibody Titer >= 10 (1/Dil) Against at Least 1, 2, 3, or 4 Serotypes With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against at least 1, 2, 3, or 4 serotypes (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.
Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3
GMTs of Dengue Virus Antibodies of FV Immune Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype with the parental dengue virus strain or for YF virus.
Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3
GMTs of Dengue Virus Antibodies of FV-Non Immune (Naïve) Participants Following Vaccination With YF Vaccine Non Immune (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.
Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3
Percentage of FV-immune Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strain or for YF virus.
Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3
Percentage of FV Non-immune (Naïve) Participants With Antibody Titer >= 10 (1/Dil) Against Each Serotype With the Parental Dengue Virus Strains After YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.
Time frame: Pre-Injection 1 and 28 days Post-Injections 2 and 3
Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Injection With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo
Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost and Irritability. Grade 3 Solicited injection site reactions: Tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling: \>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \>39.5°celsius; Vomiting: \>= episodes per 24 hours or requiring parenteral hydration; Crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses \>=3 feeds/meals or refuses most feeds/meals; Irritability: inconsolable. Solicited Injection site reaction were reported separately for Stamaril®, CYD and placebo vaccine.
Time frame: Day 0 up to 14 days post any Inj., Post Inj. 1, Post Inj. 2 and Post Inj. 3
Study participants were enrolled from 07 September 2011 to 08 March 2012 at 2 clinical sites (1 in Colombia and 1 in Peru).
| Milestone | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Started | 396 | 396 |
| Vaccinated | 394 | 393 |
| Completed | 364 | 354 |
| Not completed | 32 | 42 |
| Withdrew: Protocol violation | 7 | 5 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Withdrawal by subject | 19 | 29 |
| Withdrew: Serious adverse event | 2 | 3 |
| Withdrew: Lost to follow-up | 3 | 3 |
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dilution \[dil\]) in flavivirus non-immune participants (defined as those with YF antibodies \<10 \[1/dil\] for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus).
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo | 100.0 | 99.7 |
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>= 10 (1/dil) in participants YF-seronegative at baseline or 4-fold increase from pre- to post-YF antibody titers in participants YF-seropositive at baseline.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Percentage of All Participants With Seroconversion Against YF Antigen After Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo | 98.7 | 99.7 |
GMTs against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.
| Titers (1/dilution) | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Pre-Injection 1 | 5.64 (5.41 to 5.89) | 5.67 (5.42 to 5.93) |
| Post-Injection 1 | 369 (322 to 423) | 423 (375 to 478) |
GMTs ratios against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay.
| Ratio | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Geometric Mean Titer Ratios (GMTRs) of YF Antibodies in All Participants Following Vaccination With YF Vaccine (Stamaril®) Concomitantly With Either CYD Dengue Vaccine or a Placebo | 35.1 (30.5 to 40.4) | 39.8 (35.3 to 45.0) |
Neutralizing antibodies against YF were assessed using a YF virus plaque reduction neutralization test (YF PRNT50) assay. Seroconversion was defined as YF antibodies \>=10 (1/dil) regardless of the flavivirus status of participants at baseline.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Pre-Injection 1 | 9.0 | 9.0 |
| Post-Injection 1 | 99.5 | 99.7 |
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue plaque reduction neutralization test (PRNT) assay.
| Titers (1/dilution) | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 5.08 (4.92 to 5.25) | 5.00 (5.00 to 5.00) |
| Serotype 1; Post-Injection 2 | 47.3 (38.9 to 57.5) | 11.8 (9.82 to 14.1) |
| Serotype 1; Post-Injection 3 | 89.0 (76.4 to 104) | 61.3 (52.5 to 71.5) |
| Serotype 2; Pre-Injection 1 | 5.10 (4.96 to 5.23) | 5.00 (5.00 to 5.00) |
| Serotype 2; Post-Injection 2 | 95.5 (78.0 to 117) | 41.1 (33.2 to 51.0) |
| Serotype 2; Post-Injection 3 | 173 (142 to 211) | 150 (127 to 177) |
| Serotype 3; Pre-Injection 1 | 5.05 (4.95 to 5.16) | 5.18 (5.00 to 5.37) |
| Serotype 3; Post-Injection 2 | 118 (101 to 137) | 43.4 (36.0 to 52.3) |
| Serotype 3; Post-Injection 3 | 181 (158 to 207) | 155 (136 to 176) |
| Serotype 4; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.05 (4.96 to 5.14) |
| Serotype 4; Post-Injection 2 | 68.1 (54.6 to 84.9) | 29.8 (22.1 to 40.2) |
| Serotype 4; Post-Injection 3 | 74.0 (61.3 to 89.4) | 74.6 (62.5 to 89.1) |
GMTRs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.
| Titer ratios | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Post-Inj.2/Pre-Inj. 1 | 4.78 (3.91 to 5.84) | 1.15 (0.973 to 1.37) |
| Serotype 1; Post-Inj.3/Pre-Inj. 1 | 8.82 (7.55 to 10.3) | 6.14 (5.26 to 7.18) |
| Serotype 2; Post-Inj.2/Pre-Inj. 1 | 9.55 (7.75 to 11.8) | 3.86 (3.15 to 4.72) |
| Serotype 2; Post-Inj.3/Pre-Inj. 1 | 16.7 (13.7 to 20.4) | 15.2 (12.8 to 18.1) |
| Serotype 3; Post-Inj.2/Pre-Inj. 1 | 11.6 (9.98 to 13.5) | 4.16 (3.46 to 5.00) |
| Serotype 3; Post-Inj.3/Pre-Inj. 1 | 18.0 (15.6 to 20.8) | 15.4 (13.5 to 17.6) |
| Serotype 4; Post-Inj.2/Pre-Inj. 1 | 6.82 (5.44 to 8.55) | 2.89 (2.15 to 3.89) |
| Serotype 4; Post-Inj.3/Pre-Inj. 1 | 7.26 (6.02 to 8.77) | 7.44 (6.24 to 8.88) |
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. Seroconversion was defined as antibody titers \>= 10 (1/dil) against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 0.9 | 0.0 |
| Serotype 1; Post-Injection 2 | 92.0 | 51.3 |
| Serotype 1; Post-Injection 3 | 100.0 | 97.2 |
| Serotype 2; Pre-Injection 1 | 1.8 | 0.0 |
| Serotype 2; Post-Injection 2 | 97.3 | 86.7 |
| Serotype 2; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 3; Pre-Injection 1 | 0.9 | 3.7 |
| Serotype 3; Post-Injection 2 | 100.0 | 90.3 |
| Serotype 3; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 4; Pre-Injection 1 | 0.0 | 0.9 |
| Serotype 4; Post-Injection 2 | 91.2 | 68.1 |
| Serotype 4; Post-Injection 3 | 97.3 | 98.1 |
Neutralizing antibodies against at least 1, 2, 3, or 4 serotypes (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| At least 1 serotype; Pre-Injection 1 | 3.6 | 4.5 |
| At least 1 serotype; Post-Injection 2 | 100.0 | 93.8 |
| At least 1 serotype; Post-Injection 3 | 100.0 | 100.0 |
| At least 2 serotypes; Pre-Injection 1 | 0.0 | 0.0 |
| At least 2 serotypes; Post-Injection 2 | 100.0 | 87.6 |
| At least 2 serotypes; Post-Injection 3 | 100.0 | 100.0 |
| At least 3 serotypes; Pre-Injection 1 | 0.0 | 0.0 |
| At least 3 serotypes; Post-Injection 2 | 94.7 | 73.5 |
| At least 3 serotypes; Post-Injection 3 | 100.0 | 98.1 |
| All 4 serotypes; Pre-Injection 1 | 0.0 | 0.0 |
| All 4 serotypes; Post-Injection 2 | 85.8 | 41.6 |
| All 4 serotypes; Post-Injection 3 | 97.3 | 97.2 |
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype with the parental dengue virus strain or for YF virus.
| Titers (1/dilution) | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 5.96 (4.01 to 8.87) | 5.00 (5.00 to 5.00) |
| Serotype 1; Post-Injection 2 | 52.5 (25.0 to 110) | 17.0 (7.63 to 38.0) |
| Serotype 1; Post-Injection 3 | 81.7 (47.3 to 141) | 59.5 (44.6 to 79.5) |
| Serotype 2; Pre-Injection 1 | 6.14 (4.50 to 8.38) | 5.00 (5.00 to 5.00) |
| Serotype 2; Post-Injection 2 | 72.4 (47.4 to 111) | 74.3 (27.6 to 200) |
| Serotype 2; Post-Injection 3 | 110 (75.5 to 160) | 133 (95.7 to 186) |
| Serotype 3; Pre-Injection 1 | 5.74 (4.15 to 7.94) | 6.75 (5.05 to 9.03) |
| Serotype 3; Post-Injection 2 | 102 (54.8 to 189) | 95.8 (61.3 to 150) |
| Serotype 3; Post-Injection 3 | 143 (89.7 to 227) | 126 (91.7 to 173) |
| Serotype 4; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.41 (4.55 to 6.43) |
| Serotype 4; Post-Injection 2 | 87.1 (36 to 210) | 109 (44.7 to 265) |
| Serotype 4; Post-Injection 3 | 77.1 (24.0 to 248) | 74.3 (40.9 to 135) |
GMTs against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.
| Titers (1/dilution) | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.00 (5.00 to 5.00) |
| Serotype 1; Post-Injection 2 | 45.9 (37.0 to 57.0) | 11.4 (9.42 to 13.7) |
| Serotype 1; Post-Injection 3 | 86.6 (73.0 to 103) | 61.8 (51.5 to 74.3) |
| Serotype 2; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.00 (5.00 to 5.00) |
| Serotype 2; Post-Injection 2 | 99.0 (78.0 to 126) | 39.0 (31.4 to 48.5) |
| Serotype 2; Post-Injection 3 | 174 (139 to 218) | 157 (129 to 192) |
| Serotype 3; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.00 (5.00 to 5.00) |
| Serotype 3; Post-Injection 2 | 118 (101 to 139) | 37.9 (30.8 to 46.8) |
| Serotype 3; Post-Injection 3 | 184 (158 to 214) | 160 (138 to 187) |
| Serotype 4; Pre-Injection 1 | 5.00 (5.00 to 5.00) | 5.00 (5.00 to 5.00) |
| Serotype 4; Post-Injection 2 | 66.4 (51.8 to 85.1) | 24.0 (17.4 to 33.2) |
| Serotype 4; Post-Injection 3 | 73.0 (60.0 to 88.7) | 72.2 (59.1 to 88.1) |
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV-immune participants at baseline were defined as those participants with \>= 10 (1/dil) for at least 1 serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strain or for YF virus.
| percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 10.0 | 0.0 |
| Serotype 1; Post-Injection 2 | 90.0 | 57.1 |
| Serotype 1; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 2; Pre-Injection 1 | 20.0 | 0.0 |
| Serotype 2; Post-Injection 2 | 100.0 | 92.9 |
| Serotype 2; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 3; Pre-Injection 1 | 12.5 | 30.8 |
| Serotype 3; Post-Injection 2 | 100.0 | 100.0 |
| Serotype 3; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 4; Pre-Injection 1 | 0.0 | 7.7 |
| Serotype 4; Post-Injection 2 | 90.0 | 92.9 |
| Serotype 4; Post-Injection 3 | 88.9 | 100.0 |
Neutralizing antibodies against each serotype (Serotype 1, 2, 3 and 4) with the parental dengue virus strains were assessed using a dengue PRNT assay. FV non-immune participants at baseline were defined as those participants with \<10 (1/dil) for all serotypes (Serotype 1, 2, 3 and 4) with parental dengue virus strains and for YF virus.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Serotype 1; Pre-Injection 1 | 0.0 | 0.0 |
| Serotype 1; Post-Injection 2 | 92.6 | 51.1 |
| Serotype 1; Post-Injection 3 | 100.0 | 96.5 |
| Serotype 2; Pre-Injection 1 | 0.0 | 0.0 |
| Serotype 2; Post-Injection 2 | 96.8 | 86.7 |
| Serotype 2; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 3; Pre-Injection 1 | 0.0 | 0.0 |
| Serotype 3; Post-Injection 2 | 100.0 | 87.8 |
| Serotype 3; Post-Injection 3 | 100.0 | 100.0 |
| Serotype 4; Pre-Injection 1 | 0.0 | 0.0 |
| Serotype 4; Post-Injection 2 | 90.4 | 63.3 |
| Serotype 4; Post-Injection 3 | 97.8 | 97.7 |
Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost and Irritability. Grade 3 Solicited injection site reactions: Tenderness: cries when injected limb is moved or the movement of the injected limb is reduced; Erythema and Swelling: \>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \>39.5°celsius; Vomiting: \>= episodes per 24 hours or requiring parenteral hydration; Crying abnormal: \>3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses \>=3 feeds/meals or refuses most feeds/meals; Irritability: inconsolable. Solicited Injection site reaction were reported separately for Stamaril®, CYD and placebo vaccine.
| Percentage of participants | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Inj. site Tenderness for Stamaril®; Post-Any Inj. | 25.4 | 17.6 |
| Grd 3 Inj. site Tenderness, Stamaril®;Post-Any Inj | 0.3 | 0.3 |
| Inj. site Tenderness for CYD dengue;Post-Any Inj. | 36.5 | 28.9 |
| Grd 3 Inj site Tenderness, CYDdengue;Post-Any Inj | 0.3 | 0.0 |
| Inj. site Tenderness for placebo; Post-Any Inj. | — | 19.7 |
| Grd 3 Inj. site Tenderness, placebo;Post-Any Inj. | — | 0.3 |
| Inj. site Erythema for Stamaril®; Post-Any Inj. | 8.3 | 9.8 |
| Grd 3 Inj. site Erythema, Stamaril®;Post-Any Inj. | 0.0 | 0.0 |
| Inj. site Erythema for CYD dengue;Post-Any Inj. | 12.7 | 8.8 |
| Grd 3 Inj. site Erythema, CYD dengue;Post-Any Inj | 0.0 | 0.0 |
| Inj. site Erythema for placebo; Post-Any Inj. | — | 10.9 |
| Grd 3 Inj. site Erythema for placebo; Post-Any Inj | — | 0.0 |
| Inj. site Swelling for Stamaril®; Post-Any Inj. | 4.7 | 4.4 |
| Grd 3 Inj. site Swelling, Stamaril®; Post-Any Inj. | 0.0 | 0.0 |
| Inj. site Swelling for CYD dengue; Post-Any Inj. | 7.5 | 6.1 |
| Grd 3 Inj. site Swelling, CYD dengue; Post-Any Inj | 0.0 | 0.0 |
| Inj. site Swelling for placebo; Post-Any inj. | — | 4.9 |
| Grd 3 Inj. site Swelling for placebo; Post-Any Inj | — | 0.0 |
| Inj. site Tenderness for Stamaril®; Post-Inj. 1 | 25.4 | 17.6 |
| Grd 3 Inj. site Tenderness, Stamaril®; Post-Inj. 1 | 0.3 | 0.3 |
| Inj. site Tenderness for CYD dengue; Post-Inj. 1 | 24.9 | — |
| Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 1 | 0.0 | — |
| Inj. site Tenderness for placebo; Post-Inj. 1 | — | 19.7 |
| Grd 3 Inj. site Tenderness, placebo; Post-Inj. 1 | — | 0.3 |
| Inj. site Erythema for Stamaril®; Post-Inj. 1 | 8.3 | 9.8 |
| Grd 3 Inj.site Erythema for Stamaril®; Post-Inj. 1 | 0.0 | 0.0 |
| Inj. site Erythema for CYD dengue; Post-Inj. 1 | 8.8 | — |
| Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 1 | 0.0 | — |
| Inj. site Erythema for placebo; Post-Inj. 1 | — | 10.9 |
| Grd 3 Inj. site Erythema for placebo; Post-Inj. 1 | — | 0.0 |
| Inj. site Swelling for Stamaril®; Post-Inj. 1 | 4.7 | 4.4 |
| Grd 3 Inj.site Swelling for Stamaril®; Post-Inj. 1 | 0.0 | 0.0 |
| Inj. site Swelling for CYD dengue; Post-Inj. 1 | 4.7 | — |
| Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 1 | 0.0 | — |
| Inj. site Swelling for placebo; Post-Inj. 1 | — | 4.9 |
| Grd 3 Inj. site Swelling for placebo; Post-Inj. 1 | — | 0.0 |
| Inj. site Tenderness for CYD dengue; Post-Inj. 2 | 17.0 | 20.4 |
| Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 2 | 0.0 | 0.0 |
| Inj. site Erythema for CYD dengue; Post-Inj. 2 | 5.1 | 8.0 |
| Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 2 | 0.0 | 0.0 |
| Inj. site Swelling for CYD dengue; Post-Inj. 2 | 2.7 | 4.7 |
| Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 2 | 0.0 | 0.0 |
| Inj. site Tenderness for CYD dengue; Post-Inj. 3 | 14.6 | 16.3 |
| Grd 3 Inj. site Tenderness, CYD dengue; Post-Inj 3 | 0.3 | 0.0 |
| Inj. site Erythema for CYD dengue; Post-Inj. 3 | 3.6 | 4.2 |
| Grd 3 Inj. site Erythema, CYD dengue; Post-Inj. 3 | 0.0 | 0.0 |
| Inj. site Swelling for CYD dengue; Post-Inj. 3 | 1.6 | 2.8 |
| Grd 3 Inj. site Swelling, CYD dengue; Post-Inj. 3 | 0.0 | 0.0 |
| Fever; Post-Any Injection | 48.1 | 40.3 |
| Grade 3 Fever; Post-Any Injection | 1.3 | 0.8 |
| Vomiting; Post-Any Injection | 30.6 | 27.2 |
| Grade 3 Vomiting; Post-Any Injection | 1.3 | 2.1 |
| Crying abnormal; Post-Any Injection | 47.2 | 44.0 |
| Grade 3 Crying abnormal; Post-Any Injection | 0.5 | 1.3 |
| Drowsiness; Post-Any Injection | 36.3 | 33.9 |
| Grade 3 Drowsiness; Post-Any Injection | 0.5 | 0.0 |
| Appetite lost; Post-Any Injection | 54.7 | 50.0 |
| Grade 3 Appetite lost; Post-Any Injection | 4.7 | 3.6 |
| Irritability; Post-Any Injection | 46.4 | 46.4 |
| Grade 3 Irritability; Post-Any Injection | 1.6 | 1.6 |
| Fever; Post-Injection 1 | 26.7 | 16.5 |
| Grade 3 Fever; Post-Injection 1 | 1.1 | 0.3 |
| Vomiting; Post-Injection 1 | 16.1 | 17.1 |
| Grade 3 Vomiting; Post-Injection 1 | 0.5 | 1.0 |
| Crying abnormal; Post-Injection 1 | 32.9 | 32.1 |
| Grade 3 Crying abnormal; Post-Injection 1 | 0.5 | 1.3 |
| Drowsiness; Post-Injection 1 | 24.4 | 22.0 |
| Grade 3 Drowsiness; Post-Injection 1 | 0.5 | 0.0 |
| Appetite lost; Post-Injection 1 | 39.6 | 33.7 |
| Grade 3 Appetite lost; Post-Injection 1 | 4.4 | 3.1 |
| Irritability; Post-Injection 1 | 38.6 | 34.7 |
| Grade 3 Irritability; Post-Injection 1 | 1.6 | 1.3 |
| Fever; Post-Injection 2 | 21.2 | 22.2 |
| Grade 3 Fever; Post-Injection 2 | 0.0 | 0.3 |
| Vomiting; Post-Injection 2 | 12.4 | 8.8 |
| Grade 3 Vomiting; Post-Injection 2 | 0.5 | 0.6 |
| Crying abnormal; Post-Injection 2 | 19.7 | 21.8 |
| Grade 3 Crying abnormal; Post-Injection 2 | 0.0 | 0.0 |
| Drowsiness; Post-Injection 2 | 12.7 | 16.5 |
| Grade 3 Drowsiness; Post-Injection 2 | 0.0 | 0.0 |
| Appetite lost; Post-Injection 2 | 27.0 | 23.1 |
| Grade 3 Appetite lost; Post-Injection 2 | 0.3 | 0.3 |
| Irritability; Post-Injection 2 | 17.3 | 22.3 |
| Grade 3 Irritability; Post-Injection 2 | 0.0 | 0.0 |
| Fever; Post-Injection 3 | 20.3 | 17.8 |
| Grade 3 Fever; Post-Injection 3 | 0.3 | 0.3 |
| Vomiting; Post-Injection 3 | 7.4 | 7.3 |
| Grade 3 Vomiting; Post-Injection 3 | 0.3 | 0.6 |
| Crying abnormal; Post-Injection 3 | 15.1 | 14.6 |
| Grade 3 Crying abnormal; Post-Injection 3 | 0.0 | 0.0 |
| Drowsiness; Post-Injection 3 | 11.3 | 10.7 |
| Grade 3 Drowsiness; Post-Injection 3 | 0.0 | 0.0 |
| Appetite lost; Post-Injection 3 | 19.8 | 18.6 |
| Grade 3 Appetite lost; Post-Injection 3 | 0.0 | 0.3 |
| Irritability; Post-Injection 3 | 14.3 | 16.1 |
| Grade 3 Irritability; Post-Injection 3 | 0.0 | 0.3 |
Collected over Adverse events (AE) were collected from Day 0 (post-vaccination) of Month 0 up to 6 months post-Injection 3 (up to 573 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CYD Dengue Vaccine Group | 0/394 (0%) | 35/394 (8.9%) | 211/394 (53.6%) |
| Placebo Group | 1/393 (0.3%) | 38/393 (9.7%) | 193/393 (49.1%) |
| Event | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| PneumoniaInfections and infestations | 12/394 | 11/393 |
| Febrile convulsionNervous system disorders | 6/394 | 4/393 |
| Urinary tract infectionInfections and infestations | 4/394 | 3/393 |
| GastroenteritisInfections and infestations | 0/394 | 2/393 |
| Acute sinusitisInfections and infestations | 2/394 | 1/393 |
| CellulitisInfections and infestations | 2/394 | 1/393 |
| Thermal burnInjury, poisoning and procedural complications | 0/394 | 1/393 |
| Tongue injuryInjury, poisoning and procedural complications | 0/394 | 1/393 |
| Traumatic brain injuryInjury, poisoning and procedural complications | 0/394 | 1/393 |
| Acute lymphocytic leukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/394 | 1/393 |
| Event | CYD Dengue Vaccine Group | Placebo Group |
|---|---|---|
| Appetite lost; Post-Any injectionMetabolism and nutrition disorders | 211/394 | 193/393 |
| Fever; Post-Any InjectionGeneral disorders | 185/385 | 155/385 |
| Crying abnormal; Post-Any injectionPsychiatric disorders | 182/394 | 170/393 |
| Irritability; Post-Any injectionPsychiatric disorders | 179/394 | 179/393 |
| Injection site Tenderness for CYD dengue vaccine; Post-Any InjectionGeneral disorders | 141/386 | 105/363 |
| Drowsiness; Post-Any InjectionNervous system disorders | 140/386 | 131/386 |
| Vomiting; Post-Any injectionGastrointestinal disorders | 118/386 | 105/386 |
| NasopharyngitisInfections and infestations | 118/394 | 120/393 |
| Injection site Tenderness for Stamaril® vaccine; Post-Any InjectionGeneral disorders | 98/386 | 68/386 |
| Injection site Tenderness for placebo; Post-Any InjectionGeneral disorders | 0/394 | 76/386 |
Analysis was performed on Safety Analysis Set which included all participants who had received at least 1 dose of CYD dengue vaccine, stamaril® vaccine or placebo.
| Age, Categorical(Participants) | CYD Dengue Vaccine Group | Placebo Group | Total |
|---|---|---|---|
| <=18 years | 394 | 393 | 787 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(Months) | CYD Dengue Vaccine Group | Placebo Group | Total |
|---|---|---|---|
| Mean | 12.2 ± 0.25 | 12.2 ± 0.25 | 12.2 ± 0.25 |
| Sex: Female, Male(Participants) | CYD Dengue Vaccine Group | Placebo Group | Total |
|---|---|---|---|
| Female | 198 | 203 | 401 |
| Male | 196 | 190 | 386 |
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2011 to primary completion in Sep 2013, 24 months.
Results were first posted in Jul 2019, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yellow Fever Vaccine
Sanofi Pasteur, a Sanofi Company →